benzoxazoles has been researched along with Waldenstrom Macroglobulinemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berdeja, JG; Ghobrial, IM; Neuwirth, R; Patel, CG; Richardson, PG; Siegel, DS; Vij, R; Wolf, JL; Zohren, F | 1 |
1 trial(s) available for benzoxazoles and Waldenstrom Macroglobulinemia
| Article | Year |
|---|---|
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzoxazoles; Drug Monitoring; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Multiple Myeloma; Multiprotein Complexes; Neoplasm Grading; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Retreatment; TOR Serine-Threonine Kinases; Treatment Outcome; Waldenstrom Macroglobulinemia | 2016 |